![]() | |
Clinical data | |
---|---|
Other names | AT-007 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H10F3N3O3S2 |
Molar mass | 425.40 g·mol−1 |
3D model ( JSmol) | |
| |
|
Govorestat (AT-007) is an aldose reductase inhibitor and experimental drug to treat galactosemia [1] and sorbitol dehydrogenase deficiency. [2]
After a report circulating on the internet accused the developer Applied Therapeutics of cutting corners in its studies of the drug, the FDA put a hold on it in 2020. Applied Therapeutics said that the report was a fraudulent attempt to manipulate its stock price. [3]
![]() | |
Clinical data | |
---|---|
Other names | AT-007 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H10F3N3O3S2 |
Molar mass | 425.40 g·mol−1 |
3D model ( JSmol) | |
| |
|
Govorestat (AT-007) is an aldose reductase inhibitor and experimental drug to treat galactosemia [1] and sorbitol dehydrogenase deficiency. [2]
After a report circulating on the internet accused the developer Applied Therapeutics of cutting corners in its studies of the drug, the FDA put a hold on it in 2020. Applied Therapeutics said that the report was a fraudulent attempt to manipulate its stock price. [3]